LeMaitre Vascular, Inc
LeMaitre Vascular Inc. develops, manufactures, and sells specialized vascular devices and human tissue cryopreservation services used mainly in open vascular surgery and dialysis access. Built through a long series of acquisitions and internal development, the company has assembled a portfolio of branded products for treating peripheral vascular disease, end-stage renal disease, and related cardiovascular conditions.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaBovine, ovine, human tissue, and other biologic patches and grafts used in vascular and cardiac repair.
Polyester, ePTFE, polycarbonate, and hybrid graft products used in vascular reconstruction.
Valvulotomes, embolectomy catheters, shunts, closure systems, and related open-surgery tools.
Angioscopes, contrast injectors, and other adjunct devices used during vascular procedures.
RestoreFlow processing, preservation, and cryopreservation services for human vascular and cardiac tissue.
Asiakkaat
The core customer is the vascular surgeon, who buys LeMaitre products for open vascular surgery and dialysis access procedures. The company also sells selected products to cardiac surgeons, general surgeons, neurosurgeons, and, to a lesser degree, interventional cardiologists as it expands beyond its original call point. Hospitals, clinics, and distributors are the purchasing channels, with direct sales representatives handling most territories.
Primary call point buying valvulotomes, grafts, catheters, and patches for peripheral vascular disease and dialysis access.
End customers and care settings that purchase the devices and services for surgical use, often via direct sales or consignment.
Buy biologic patches and cryopreservation-related products such as RestoreFlow and CardioCel for cardiac applications.
Purchase in markets without direct sales coverage and resell into hospitals and clinics.
General surgeons and neurosurgeons buy selected niche products where the portfolio fits their procedures.
Strategia
LeMaitre’s strategy is to deepen its focus on niche vascular products, expand direct sales coverage, and add complementary products through acquisitions. Management also aims to grow in adjacent call points and new countries while maintaining a portfolio mix that is less dependent on any single product line.
Acquisitions have been a primary growth engine and broaden the portfolio without relying on one product.
Direct coverage supports pricing, surgeon relationships, and market penetration in new countries.
Biologic offerings are a large share of sales and can extend the company beyond the core vascular surgeon base.
Maantiede
Q1/2026LeMaitre sells globally, with principal markets in the United States, Europe, Canada, and Asia Pacific. About 43% of 2025 sales occurred outside the United States, and roughly 95% of net sales were generated in territories covered by direct sales representatives, which makes field coverage a key driver of growth and pricing power. The company also operates regional headquarters and sales offices in Europe and Asia Pacific, while manufacturing is concentrated in the United States with one key third-party supply relationship in Germany.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
The business depends on a narrow set of specialized medical procedures, so competitive pressure, reimbursement changes, and shifts toward endovascular techniques can erode demand for open-surgery products. Growth also depends on acquisitions, regulatory approvals, and reliable sourcing of biologic and tissue-based inputs, while international exposure creates foreign exchange, compliance, and distributor risks.
- Acquisition execution riskVaikutus: KorkeaTodennäköisyys: Korkea
A meaningful part of growth has come from acquisitions, which may be harder to source or integrate.
Kohdistuu: Portfolio expansion strategy
- Competitive pressure and procedure mix shiftVaikutus: KorkeaTodennäköisyys: Kohtalainen
Open vascular products compete with endovascular devices and larger rivals with broader resources.
Kohdistuu: Core vascular surgery portfolio
- Supply and donor tissue constraintsVaikutus: KorkeaTodennäköisyys: Kohtalainen
Biologic and cryopreservation products rely on limited-source suppliers and tissue availability.
Kohdistuu: RestoreFlow and biologic grafts
- Regulatory and product liability exposureVaikutus: KorkeaTodennäköisyys: Kohtalainen
Medical devices and human tissue services face FDA, foreign regulatory, and liability risk.
Kohdistuu: All product lines and processing services
- Foreign exchange volatilityVaikutus: Keskitaso
A large share of sales is outside the U.S. and denominated in foreign currencies.
Kohdistuu: Europe and Asia Pacific sales
Kirjanpito
Harkinnanvaraiset erätNet sales depend on when control transfers and on estimates for returns and allowances.
Vaikutus: Can shift quarterly revenue and gross margin
Future earn-out liabilities are recorded at fair value and remeasured each period.
Vaikutus: Can create operating income volatility
Medical device inventory and related deferred costs require judgment on realizability.
Vaikutus: Affects cost of sales and asset carrying values
A large share of sales occurs outside the U.S. and is exposed to exchange-rate changes.
Vaikutus: Affects reported revenue and operating results
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
AtriCure, Inc.
ATRC · Surgical & Medical Instruments & Apparatus
AtriCure designs and sells surgical devices used by cardiac surgeons and electrophysiologists to treat atrial fibrillation, manage the left atrial appendage, and reduce post-operative pain.
Artivion, Inc
AORT · Surgical & Medical Instruments & Apparatus
Baxter International Inc
BAX · Surgical & Medical Instruments & Apparatus
Merit Medical Systems, Inc
MMSI · Surgical & Medical Instruments & Apparatus
Merit Medical Systems designs, manufactures, and markets proprietary medical devices used in interventional, diagnostic, and therapeutic procedures.
Humacyte, Inc.
HUMA · Biological Products, (No Diagnostic Substances)
Anteris Technologies Global Corp.
AVR · Orthopedic, Prosthetic & Surgical Appliances & Supplies
Päivitetty: 24.9.2026